Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals

被引:5
作者
Lithy, Rania M. [1 ]
Elbaz, Tamer [1 ]
Abdelmaksoud, Ahmed H. [2 ]
Nabil, Mohamed M. [1 ]
Rashed, Noha [1 ]
Omran, Dalia [1 ]
Kaseb, Ahmed O. [3 ]
Abdelaziz, Ashraf O. [1 ]
Shousha, Hend, I [1 ]
机构
[1] Cairo Univ, Fac Med, Endem Med Dept, Cairo, Egypt
[2] Cairo Univ, Fac Med, Diagnost & Intervent Radiol Dept, Cairo, Egypt
[3] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
关键词
direct acting antivirals; hepatocellular carcinoma; hepatitis C virus; recurrence; time interval; SUSTAINED VIROLOGICAL RESPONSE; EARLY TUMOR RECURRENCE; UNEXPECTED HIGH-INCIDENCE; CIRRHOTIC-PATIENTS; THERAPY; RISK; HCC; CHEMOEMBOLIZATION; DECREASES; ABLATION;
D O I
10.1097/MEG.0000000000001972
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Conflicting studies were proposed either suggested or denied the relationship between early hepatocellular carcinoma (HCC) recurrence and the use of direct-acting antivirals (DAAs) for chronic hepatitis C management Aim of the study To evaluate HCC recurrence rate post-DAAs and potential predictive factors. Study This prospective cohort study included all HCC patients achieved complete response attending our multidisciplinary HCC clinic, Cairo University, from November 2013 to February 2018. Group I (60 patients) who received DAAs after HCC ablation and group II (273 patients) who were DAAs-untreated. We studied factors that could play a role in HCC recurrence. Results The sustained virological response rate was 88.3% among DAA-treated patients. HCC recurrence rate was 45% in the post-DAA group vs. 19% in the non-DAAs group; P < 0.001. Mean survival was significantly higher in the post-DAA group (34.23 +/- 16.16 vs. 23.92 +/- 13.99 months respectively; P value <0.001). There was a significant correlation between HCC recurrence rate and age, male gender, mean size of tumors and time interval between complete HCC ablation and occurrence of HCC recurrence. Conclusion Our study reports high rate of HCC recurrence post-DAA therapy in patients treated with transarterial chemoembolization but not in those treated with curative measures. DAA therapy after curative treatment for HCC led to significantly earlier HCC recurrence, which correlated with specific clinic-pathologic features in our prospective single-institution study. However, future independent prospective randomized studies are warranted to evaluate this correlation which may lead to a change in the current standard-of-care approach to patients with hepatitis C virus-related HCC.
引用
收藏
页码:227 / 234
页数:8
相关论文
共 35 条
  • [1] Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis
    Abdelaziz, Ashraf Omar
    Nabeel, Mohamed Mahmoud
    Elbaz, Tamer Mahmoud
    Shousha, Hend Ibrahim
    Hassan, Eman Medhat
    Mahmoud, Sherif Hamdy
    Rashed, Noha Ali
    Ibrahim, Mostafa Mohamed
    Abdelmaksoud, Ahmed Hosni
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2015, 50 (04) : 479 - 484
  • [2] Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience
    Abdelaziz, Ashraf Omar
    Elbaz, Tamer Mahmoud
    Shousha, Hend Ibrahim
    Ibrahim, Mostafa Mohamed
    El-Shazli, Mostafa Abdel Rahman
    Abdelmaksoud, Ahmed Hosni
    Aziz, Omar Abdel
    Zaki, Hisham Atef
    Elattar, Inas Anwar
    Nabeel, Mohamed Mahmoud
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (09) : 3915 - 3920
  • [3] The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
    Armstrong, Gregory L.
    Wasley, Annemarie
    Simard, Edgar P.
    McQuillan, Geraldine M.
    Kuhnert, Wendi L.
    Alter, Miriam J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) : 705 - 714
  • [4] Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
    Bruix, J
    Sherman, M
    Llovet, JM
    Beaugrand, M
    Lencioni, R
    Burroughs, AK
    Christensen, E
    Pagliaro, L
    Colombo, M
    Rodés, J
    [J]. JOURNAL OF HEPATOLOGY, 2001, 35 (03) : 421 - 430
  • [5] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [6] Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study
    Cabibbo, G.
    Petta, S.
    Calvaruso, V.
    Cacciola, I.
    Cannavo, M. R.
    Madonia, S.
    Distefano, M.
    Larocca, L.
    Prestileo, T.
    Tine, F.
    Bertino, G.
    Giannitrapani, L.
    Benanti, F.
    Licata, A.
    Scalisi, I.
    Mazzola, G.
    Cartabellotta, F.
    Alessi, N.
    Barbara, M.
    Russello, M.
    Scifo, G.
    Squadrito, G.
    Raimondo, G.
    Craxi, A.
    Di Marco, V.
    Camma, C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (07) : 688 - 695
  • [7] Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
    Cabibbo, Giuseppe
    Celsa, Ciro
    Calvaruso, Vincenza
    Petta, Salvatore
    Cacciola, Irene
    Cannavo, Maria Rita
    Madonia, Salvatore
    Rossi, Margherita
    Magro, Bianca
    Ini, Francesca
    Distefano, Marco
    Larocca, Licia
    Prestileo, Tullio
    Malizia, Giuseppe
    Bertino, Gaetano
    Benanti, Francesco
    Licata, Anna
    Scalisi, Ignazio
    Mazzola, Giovanni
    Di Rosolini, Maria Antonietta
    Alaimo, Giuseppe
    Averna, Alfonso
    Cartabellotta, Fabio
    Alessi, Nicola
    Guastella, Salvatore
    Russello, Maurizio
    Scifo, Gaetano
    Squadrito, Giovanni
    Raimondo, Giovanni
    Trevisani, Franco
    Craxi, Antonio
    Di Marco, Vito S.
    Camma, Calogero
    [J]. JOURNAL OF HEPATOLOGY, 2019, 71 (02) : 265 - 273
  • [8] Cholongitas E, 2014, ANN GASTROENTEROL, V27, P331
  • [9] Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
    Conti, Fabio
    Buonfiglioli, Federica
    Scuteri, Alessandra
    Crespi, Cristina
    Bolondi, Luigi
    Caraceni, Paolo
    Foschi, Francesco Giuseppe
    Lenzi, Marco
    Mazzella, Giuseppe
    Verucchi, Gabriella
    Andreone, Pietro
    Brillanti, Stefano
    [J]. JOURNAL OF HEPATOLOGY, 2016, 65 (04) : 727 - 733
  • [10] Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis
    El Kassas, M.
    Funk, A. L.
    Salaheldin, M.
    Shimakawa, Y.
    Eltabbakh, M.
    Jean, K.
    El Tahan, A.
    Sweedy, A. T.
    Afify, S.
    Youssef, N. F.
    Esmat, G.
    Fontanet, A.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2018, 25 (06) : 623 - 630